Multimodality assessment and treatment of chemotherapy-induced cardiotoxicity

Future Cardiology

Volumn 11, Issue 4, 2015, Pages 421-424

  Storozynsky, Eugene ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Biomarkers; Cardiotoxicity; Chemotherapy; Heart failure; Imaging; SERCA 2

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFECTIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMCIROMAB PENTETATE; IODOFILTIC ACID I 123; PHOSPHOLAMBAN; TRASTUZUMAB; ANTINEOPLASTIC AGENT;

APOPTOSIS; BREAST CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CARDITIS; CHEMOTHERAPY INDUCED CARDIOTOXICITY; CONGESTIVE HEART FAILURE; ECG ABNORMALITY; ECHOCARDIOGRAPHY; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT HYPERTENSION; MITOCHONDRION; NOTE; PERICARDIUM; PRIORITY JOURNAL; QT PROLONGATION; SOLID TUMOR; VASOSPASM; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; HUMANS; NEOPLASMS;

EID: 84939426681     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/FCA.15.49     Document Type: Note

References (21)

1. Yeh ETH, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J. Am. Coll. Cardiol. 53(24), 2231-2247 (2009).
2. Lenihan DJ, Oliva S, Chow EJ, Cardinale D. Cardiac toxicity in cancer survivors. Cancer 119(S11), 2131-2142 (2013).
3. Berardi R, Caramanti M, Savini A et al. State of the art for cardiotoxicity due to chemotherapy and to targeted therapies: a literature review. Crit. Rev. Oncol. Hematol. 88, 75-86 (2013).
4. Mouhayar E, Salahudeen A. Hypertension in cancer patients. Tex. Heart Ins. J. 38, 263-265 (2011).
5. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More malignant than cancer? Five-year survival following a first admission for heart failure. Eur. J. Heart Fail. 3(3), 315-322 (2001).
6. Shareef MA, Lucman AA, Poizat C. Cardiac SERCA2A/B: therapeutic targets for heart failure. Eur. J. Pharm. 724, 1-8 (2014).
7. Brittsan AG, Kranias EG. Phospholamban and cardiac contractile function. J. Mol. Cell Cardiol. 32, 2131-2139 (2000).
8. Arai M, Tomaru K, Takizawa T et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell Cardiol. 30(2), 243-254 (1998).
9. Koitabashi N, Arai M, Tomaru K et al. Carvedilol effectively blocks oxidative stressmediated downregulation of sarcoplasmic reticulum Ca2+-ATPase 2 gene transcription through modification of Sp1 binding. Biochem. Biophys. Res. Commun. 328(1), 116-124 (2005).
10. Ky B, Putt M, Sawaya H et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J. Am. Coll. Cardiol. 63(8), 809-816 (2013).
11. Calabro P, Golia E, Yeh ETH. Role of c-reactive protein in acute myocardial infarction and stroke: possible therapeutic approaches. Curr. Pharm. Biotech. 13(1), 4-16 (2012).
12. Ridker PM, Danielson E, Fonseca FA et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the Jupiter trial. Lancet 373(9670), 1175-1182 (2009).
13. Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J. Am. Coll. Cardiol. 60(23), 2384-2390 (2012).
14. Acar Z, Kale A, Turgut M et al. Efficiency of atorvastatin in the protection of anthracyclineinduced cardiomyopathy. J. Am. Coll. Cardiol. 58(9), 988-989 (2011).
15. Felker G, Ahmad T, Anstrom KJ et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JACC Heart Fail. 2(5), 457-465 (2014).
16. Bu'Lock FA, Mott MG, Oakhill A and Martin RP. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms, and pathophysiology. Br. Heart J. 73(4), 340-350 (1995).
17. Tassan-Mangina S, Codorean D, Metivier M et al. Tissue doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur. J. Echo 7(2), 141-146 (2006).
18. Thavendiranathan P, Poulin F, Lim K, Plana J, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J. Am. Coll. Cardiol. 63(25-PA), 2751-2768 (2014).
19. Schwartz RG, Jain D, Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively. J. Nucl. Cardiol. 20(3), 443-464 (2013).
20. Kalay N, Basar E, Ozdogru I et al. Protective effects of carvedilol against anthracyclineinduced cardiomyopathy. J. Am. Coll. Cardiol. 48(11), 2258-2262 (2006).
21. Cardinale D, Colombo A, Sandri MT et al. Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114(23), 2474-2481 (2006).